Also noted on generics: 6 April 2012

Generics/General | Posted 06/04/2012 post-comment0 Post your comment

Tropsium XR patents declared invalid
Watson Pharmaceuticals confirmed in early April 2012 that the United States District Court for the District of Delaware has ruled that four patents for Sanctura XR (trospium chloride extended-release capsules) are invalid. Watson’s Abbreviated New Drug Application for a generic version of the overactive bladder treatment is pending with FDA.

According to IMS Health data Sanctura XR had US sales of approximately US$68 million for the twelve months ending 29 February 2012.

Source: Watson

GSK and Pfizer sue Hikma over argatroban patent
GlaxoSmithKline (GSK) and Pfizer sued Hikma Pharmaceuticals for planning to sell an injectable blood-clot treatment that the drugmakers say infringes a patent licensed by GSK for argatroban.

Generics maker Hikma received FDA approval on 5 January 2012 for the generic version of argatroban, infringing on a patent that expires in 2014, according to the complaint filed on 30 March 2012 in federal court in Trenton, New Jersey, USA.

Source: Bloomberg, Hikma

Ranbaxy resumes export of atorvastatin from India to US
Ranbaxy Laboratories (Ranbaxy) announced on 2 April 2012 that it had started shipping generic atorvastatin to the US from its newly FDA-approved plant in India. The company had been selling generic atorvastatin in the US since December 2011 from its plant in the US but exports from its plants in India were banned in 2009 due to issues with Good Manufacturing Practice.

Mr Arun Sawhney, CEO and Managing Director at Ranbaxy, said this market is ‘a significant milestone for Ranbaxy’.

Related articles

Teva gains tentative approval for generic atorvastatin

Ranbaxy gets FDA approval and launches generic atorvastatin

Source: Ranbaxy

Teva launches generics of Sanofi blood pressure drugs
On 2 April 2012, Teva announced commercial launch of generic versions of sanofi-aventis’ high blood pressure treatments, Avapro (irbesartan) and Avalide (irbesartan-hydrochlorothiazide) tablets. According to IMS Health data, the brand-name products had annual sales in the US of approximately US$464 million and US$124 million, respectively.

As the first company to file Abbreviated New Drug Applications for both of these products, Teva will now enjoy a 180-day period of marketing exclusivity before other generics can enter the market.

Source: Teva

Ranbaxy launches rosuvastatin in Canada
Ranbaxy Laboratories (Ranbaxy) announced on 31 March 2012 that its Canadian subsidiary had received approval from Health Canada to manufacture and market a generic version of AstraZeneca’s blockbuster cholesterol-reducing drug Crestor (rosuvastatin) to the Canadian healthcare system.

According to Ranbaxy, sales of branded Crestor in Canada in 2011 were CA$742.2 million.

Related articles

Generic atorvastatin may be better than Crestor

Sun gains tentative approval for generic Crestor

Generics lose battle against AstraZeneca’s Crestor (rosuvastatin)

Source: Ranbaxy

Sun and Cipla drugs recalled in US
Some of India’s top drug manufacturers are having to deal with drug recalls after FDA found impurities in their drugs. Sun Pharma has recalled about 155,000 bottles of an eye solution. While Teva and US-based Eagle Pharmaceuticals have respectively recalled cancer therapy flutamide and anticoagulant argatroban injection, both made at India-based Cipla’s Goa plant.

Source: The Economic Times

comment icon Comments (0)
Post your comment
Related content
Generic drug growth in Brazil and Venezuela
53 MD002445
Generics/General Posted 15/09/2023
Pharmaceutical manufacturing companies in Brazil
91 AA007225
Generics/General Posted 26/08/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010